ArticleAmerican journal of translational research2025

Comparison of survival benefit and safety profile between lenvatinib and donafenib as conversion therapy in patients with hepatocellular carcinoma.

Yuehong Hou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.